US EditionSenseonics posts Q2 beat, submits 365-day CGM for CE mark
Summary by Drug Delivery Business
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Senseonics posts Q2 beat, submits 365-day CGM for CE mark
Senseonics (NYSE:SENS) shares dipped after hours today on first-quarter results that beat revenue projections on Wall Street. Shares of SENS fell 5% to 70¢ apiece in post-market trading today. The Germantown, Maryland-based long-term implantable continuous glucose monitor maker reported losses of $14.3 million. That equals 2¢ per share on sales of $6.26 million for the three months ended March 31, 2025. Senseonics recorded a more than $4 million…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
